S&P 500   4,568.86 (+0.04%)
DOW   36,146.01 (+0.06%)
QQQ   386.48 (-0.21%)
AAPL   192.52 (-0.47%)
MSFT   368.94 (-0.96%)
META   318.91 (+0.19%)
GOOGL   130.51 (-0.37%)
AMZN   145.08 (-1.23%)
TSLA   243.35 (+1.94%)
NVDA   462.86 (-0.60%)
NIO   8.15 (+9.69%)
BABA   72.23 (-0.21%)
AMD   119.31 (+0.79%)
T   17.03 (-1.10%)
F   10.80 (+1.89%)
MU   73.73 (+0.05%)
CGC   0.70 (+5.07%)
GE   120.41 (+0.15%)
DIS   92.06 (+1.40%)
AMC   6.91 (-1.57%)
PFE   29.27 (+0.62%)
PYPL   59.80 (+3.25%)
XOM   99.18 (-1.25%)
S&P 500   4,568.86 (+0.04%)
DOW   36,146.01 (+0.06%)
QQQ   386.48 (-0.21%)
AAPL   192.52 (-0.47%)
MSFT   368.94 (-0.96%)
META   318.91 (+0.19%)
GOOGL   130.51 (-0.37%)
AMZN   145.08 (-1.23%)
TSLA   243.35 (+1.94%)
NVDA   462.86 (-0.60%)
NIO   8.15 (+9.69%)
BABA   72.23 (-0.21%)
AMD   119.31 (+0.79%)
T   17.03 (-1.10%)
F   10.80 (+1.89%)
MU   73.73 (+0.05%)
CGC   0.70 (+5.07%)
GE   120.41 (+0.15%)
DIS   92.06 (+1.40%)
AMC   6.91 (-1.57%)
PFE   29.27 (+0.62%)
PYPL   59.80 (+3.25%)
XOM   99.18 (-1.25%)
S&P 500   4,568.86 (+0.04%)
DOW   36,146.01 (+0.06%)
QQQ   386.48 (-0.21%)
AAPL   192.52 (-0.47%)
MSFT   368.94 (-0.96%)
META   318.91 (+0.19%)
GOOGL   130.51 (-0.37%)
AMZN   145.08 (-1.23%)
TSLA   243.35 (+1.94%)
NVDA   462.86 (-0.60%)
NIO   8.15 (+9.69%)
BABA   72.23 (-0.21%)
AMD   119.31 (+0.79%)
T   17.03 (-1.10%)
F   10.80 (+1.89%)
MU   73.73 (+0.05%)
CGC   0.70 (+5.07%)
GE   120.41 (+0.15%)
DIS   92.06 (+1.40%)
AMC   6.91 (-1.57%)
PFE   29.27 (+0.62%)
PYPL   59.80 (+3.25%)
XOM   99.18 (-1.25%)
S&P 500   4,568.86 (+0.04%)
DOW   36,146.01 (+0.06%)
QQQ   386.48 (-0.21%)
AAPL   192.52 (-0.47%)
MSFT   368.94 (-0.96%)
META   318.91 (+0.19%)
GOOGL   130.51 (-0.37%)
AMZN   145.08 (-1.23%)
TSLA   243.35 (+1.94%)
NVDA   462.86 (-0.60%)
NIO   8.15 (+9.69%)
BABA   72.23 (-0.21%)
AMD   119.31 (+0.79%)
T   17.03 (-1.10%)
F   10.80 (+1.89%)
MU   73.73 (+0.05%)
CGC   0.70 (+5.07%)
GE   120.41 (+0.15%)
DIS   92.06 (+1.40%)
AMC   6.91 (-1.57%)
PFE   29.27 (+0.62%)
PYPL   59.80 (+3.25%)
XOM   99.18 (-1.25%)

Fusion Antibodies Share Price, News & Analysis (LON:FAB)

GBX 4.68
-0.20 (-4.00%)
(As of 04:27 PM ET)
Compare
Today's Range
4.50
▼
5.50
50-Day Range
3.30
▼
7.33
52-Week Range
3.02
▼
70
Volume
1.37 million shs
Average Volume
970,896 shs
Market Capitalization
£2.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsHeadlinesInsider Trades

FAB stock logo

About Fusion Antibodies Stock (LON:FAB)

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. It serves pharmaceutical, biotech, and diagnostic companies. The company has a collaboration partnership with Celonic AG. The company was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.

FAB Stock Price History

FAB Stock News Headlines

December 6, 2023 | americanbankingnews.com
Simon Gordon Douglas Buys 100,565 Shares of Fusion Antibodies plc (LON:FAB) Stock
November 28, 2023 | marketwatch.com
Fusion Antibodies Shares Rise on US Cancer Institute Collaboration
December 6, 2023 | Edge On The Street (Ad)
Henry Ford Would NEVER Have Seen This Coming
In 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.
November 9, 2023 | msn.com
Belfast antibodies firm Fusion flags up 'challenges'
October 31, 2023 | news.yahoo.com
New cancer therapy using antibody could offer a less toxic treatment option, study shows
October 1, 2023 | finance.yahoo.com
Fusion Antibodies Full Year 2023 Earnings: UK£0.10 loss per share (vs UK£0.046 loss in FY 2022)
September 29, 2023 | marketwatch.com
Fusion Antibodies Pretax Loss Widens on Higher Costs, Lower Revenue
August 23, 2023 | markets.businessinsider.com
Introducing NeoMab™: GemPharmatech's Innovative Antibody Gene Humanized Mouse Model
December 6, 2023 | Edge On The Street (Ad)
Henry Ford Would NEVER Have Seen This Coming
In 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.
August 21, 2023 | marketwatch.com
Fusion Antibodies Signs Combined Screening Service With AI Company
August 16, 2023 | finance.yahoo.com
Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers
May 19, 2023 | marketwatch.com
Fusion Antibodies Shares Dive After Discounted Placing
May 16, 2023 | marketwatch.com
Antibody Engineering Services Market Growth, Business Overview 2023, and Forecast to 2030 | Fusion Antibodies, Absolute Antibody, Creative Biolabs
April 28, 2023 | forbes.com
Resurrection Of Covid Antibody Therapy: IgG3 Fc Fusion To The Rescue
April 27, 2023 | marketwatch.com
Antibody Engineering Services Market Growth by 2031
April 20, 2023 | marketwatch.com
Antibody Engineering Services Market Projected Industry Expansion and Factors Impacting Competitors, Alongside Promising Strategies Until 2029
April 19, 2023 | marketwatch.com
Recombinant Therapeutic Antibodies and Proteins Market: Key Players and Strategies for Future Growth by 2023-2030
April 13, 2023 | msn.com
Fusion (FUSN) to Begin Clinical Study on Targeted Alpha Therapy
March 21, 2023 | marketwatch.com
Fusion Antibodies Files Patent Application for Cancer Treatment Antibodies
March 15, 2023 | foxnews.com
Sleep deprivation could reduce vaccine antibodies, new study found
March 6, 2023 | marketwatch.com
Fusion Antibodies Sees Lower FY 2023 Revenue On Order Delays
March 1, 2023 | marketwatch.com
In Depth Research on Recombinant Therapeutic Antibodies and Proteins Market Report 2023-2029
February 6, 2023 | marketwatch.com
Antibody Engineering Services Market | Rising Sales of the Industry Are Set To Drive for Growth Prospects and Innovations
January 21, 2023 | forbes.com
Bivalent Antibodies For Covid-19: Two Hands Are Better Than One
November 28, 2022 | finance.yahoo.com
Cancer Monoclonal Antibodies Market Report 2022: Rising Preference for Personalized Medicines Provides Boost to Sector
November 3, 2022 | forbes.com
New Monoclonal Antibody Cocktail Neutralizes Lassa Virus
October 27, 2022 | forbes.com
As Protection From Current Covid-19 Monoclonal Antibody Treatments Fades, The Discovery Of A New Class Of Antibodies Brings Hope
See More Headlines
Receive FAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fusion Antibodies and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:FAB
CUSIP
N/A
CIK
N/A
Web
fusionantibodies.com
Phone
+44-28-90432800
Fax
N/A
Employees
48
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-2,600,000.00
Net Margins
-89.49%
Pretax Margin
N/A
Return on Equity
-108.01%
Return on Assets
-51.20%

Debt

Debt-to-Equity Ratio
6.68
Current Ratio
1.92
Quick Ratio
2.36

Sales & Book Value

Annual Sales
£2.90 million
Price / Sales
0.96
Cash Flow
GBX 0.52 per share
Price / Cash Flow
9.02
Book Value
GBX 4 per share
Price / Book
1.17

Miscellaneous

Outstanding Shares
59,450,000
Free Float
N/A
Market Cap
£2.78 million
Optionable
Not Optionable
Beta
0.56
The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Adrian Robert Kinkaid Ph.D. (Age 56)
    CEO & Director
    Comp: $183.49k
  • Dr. Richard John Buick Ph.D. (Age 47)
    Chief Scientific Officer & Director
    Comp: $127k
  • Prof. Jim Johnston
    Founder
  • Mr. Stephen Barry Smyth (Age 48)
    Company Secretary, Interim CFO & Director
  • Ms. Nicola Hamilton
    Operations Manager
  • Dr. Paul Gerard Kerr (Age 50)
    Consultant
    Comp: $180.38k

Key Competitors

View All Competitors

Insiders

View All Insider Transactions














FAB Stock Analysis - Frequently Asked Questions

How have FAB shares performed in 2023?

Fusion Antibodies' stock was trading at GBX 45 at the beginning of 2023. Since then, FAB stock has decreased by 89.3% and is now trading at GBX 4.80.
View the best growth stocks for 2023 here.

What other stocks do shareholders of Fusion Antibodies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Antibodies investors own include D4t4 Solutions (D4T4), Aminex (AEX), Eurasia Mining (EUA), Dril-Quip (DRQ), 4D pharma (DDDD), ABM Industries (ABM), Card Factory (CARD), Blockchain Worldwide (BLOC), ATTRAQT Group (ATQT) and

How do I buy shares of Fusion Antibodies?

Shares of FAB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:FAB) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -